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ABSTRACT
A Role for Serotonin in the Hypothalamic
-Pituitary-Adrenal
Response to Insulin Stress
May 1983
Rachel Yehuda, B.A., Touro College
M.S., University of Massachusetts
Directed by: Professor Jerrold S. Meyer
Controversy exists concerning the possible involvement of
serotonin in the pituitary-adrenocortical response to stress. In
the present research, a variety of physiological and pharmacological
manipulations were used in male rats to study the role of this
neurotransmitter in the adrenocortical response to insulin-induced
hypoglycemia. First, the effect of insulin stress on hypothalamic
5-HT metabolism was examined, and an increased turnover was found
as determined by an enhanced accumulation of 5-HT following mono-
amine oxidase inhibition. The corticos terone response to insulin was
potentiated by prior administration of L-tryptophan, and blocked by
pretreatment with valine, an amino acid that competes with trypto-
phan for transport across the blood-brain barrier. Treatment with
the 5-HT receptor blocker methysergide, or serotonin depletion by
intraventricular injection of 5 , 7-dihydroxy tryptamine significantly
attenuated the insulin- induced rise in circulating corticosterone.
It therefore appears that the pituitary-adrenal response to insulin
is mediated at least in part, by 5-HT, and may be dependent on
increased uptake of tryptophan by the brain.
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CHAPTER I
INTRODUCTION
Although many neurotransmitters are thought to play a role in
regulating the hypothalamic-pituitary-adrenal (HPA) axis in res-
ponse to stress, investigators to date cannot completely agree on
what these neurotransmitters are, and the relative contribution of
each. There is even controversy concerning the excitatory or in-
hibitory actions of the neurotransmitters which have been
suggested to regulate this endocrine system. In order to under-
stand the controversies which have ensued over the past two decades
concerning the neural regulation of the hypothalamic-pituitary-
adrenocortical system, it is necessary to briefly review some of
the characteristics of this system as well as the limitations of
the methods and techniques which have been used to study it.
The HPA axis . The hypothalamus receives various neural inputs
which control the secretion of corticotropic releasing hormone
(CRH), a Al-amino acid peptide (Vale et al., 1981). This peptide
is released from specialized CRH-containing neurons which have
been detected in the anterior parvocellular region of the para-
ventricular nucleus complex in the rat hypothalamus as well as in
the median eminence (Bloom et al., 1982). CRH reaches the anterior
1
2pituitary via the hypophyseal portal circulation, where it stim-
ulates the synthesis and release of adrenocorticotropic hormone
(ACTH)
.
In response to ACTH, the adrenal glands produce and
release glucocorticoids (corticosteroids).
In addition to stress-induced hormone release, other aspects
of the HPA system involve the regulation of basal circadian CRH
release and feedback suppression of CRH. The neural inputs which
regulate these different aspects of HPA hormone secretion are
thought to be at least partially independent of one another.
Evidence suggests that basal circadian periodicity involves reg-
ulation by the suprachiasmatic nucleus, whereas feedback regulation
occurs via limbic system inputs (for review, see Krieger, 1977).
While the following discussion will focus mainly on the reg-
ulation of the HPA stress-response, these other aspects of HPA
hormone secretion need to be mentioned because of their potential
effects on the corticosteroid response to stress. For example,
stress induced hormone release may differ according to the relative
amounts of corticosteroids present in the circulation at the time
of stress exposure (Vernikos-Danellis & Heybach, 1980) . Adrenal
sensitivity to ACTH also varies in response to such factors as
time of day (Dallman et al., 1976). Thus, although the central
mechanisms which regulate circadian rhythmicity may be distinct
from those regulating the stress response, stress-induced adreno-
cortical secretion may be affected by diurnal variation. Addition-
ally, it is important to note that these characteristics may share
one or more neurotransmitters, and as such may shed light on stress
induced HPA function. Indeed, evidence has been accumulating to
suggest the involvement of one particular neurotransmitter in all
areas of HPA function. This neurotransmitter is serotonin (5-HT)
.
Techniques used to study serotonergic regulation of HPA hormone
release. A variety of techniques have attempted to elucidate a
role for 5-HT in hypothalamic-pituitary-adrenocortical functioning
in response to stress. These studies fall into four categories:
* in vitro studies of hypothalamic CRH secretion in response
to 5-HT and 5-HT altering drugs
* studies on the effect of 5-HT and 5-HT altering drugs on
HPA hormone secretion in unstimulated animals
* studies on the effect of 5-HT and 5-HT altering drugs
under conditions where the HPA system has been stimulated
* studies on the ability of stress to affect brain 5-HT
metabolism.
In vitro studies of hypothalamic CRH secretion in response to 5-HT
and 5-HT altering drugs
. A number of investigators have measured
CRH act ivity in isolated hypothalami of adrenalectomized rats in
response to various neurotransmitters and drugs. In general these
studies have been consistent in obtaining evidence which supports
a stimulatory role for 5-HT. Jones, Hillhouse and Burden (1976)
and Buckingham and Hodges (1979) found that 5-HT could stimulate
CRH release in a dose-dependent manner. This effect was
antagonized by the 5-HT receptor blocker methysergide.
In a more recent study Holmes et al. (1982) have found that
5-HT induced CRH activity could be potentiated by chlorimipramine
or d-fenfluramine, two drugs which are thought to cause an in-
creased concentration of 5-HT in the synaptic cleft. (The former
drug is a known 5-HT reuptake inhibitor, and the latter drug is
presumably a 5-HT releasing drug.) In addition, treatment with
5,7-dihydroxytryptamine (5,7-DHT), a 5-HT neurotoxin, enhanced
CRH secretion in response to 5-HT administration — an effect
which is probably due to increased sensitivity of 5-HT post-
synaptic receptors following 5,7-DHT administration.
While a 5-HT stimulation can be clearly seen in these
studies, there is some dispute as to the relative importance of
other neurotransmitter systems which may or may not be influencing
5-HT induced CRH secretion. For example in the aforementioned
study by Jones et al., 5-HT stimulated CRH release could be atten-
uated by two cholinergic antagonists, hexomethonium and atropine.
Jones et al. therefore concluded that while 5-HT acts to stimulate
hypothalamic CRH secretion, such stimulation may be mediated
through a cholinergic interneuron. This conclusion is consistent
with the finding of Hillhouse, Burden and Jones (1974) that
acetylcholine (ACh) itself stimulates the release of CRH.
Buckingham and Hodges were able to replicate this latter finding,
however they were unable to block 5-HT induced CRH release with
anticholinergic drugs. Thus, they concluded that cholinergic cells
may be involved in CRH regulation but not necessarily in the
capacity of interneurons.
In the study of Buckingham and Hodges ACh induced CRH release
was antagonized not only by anticholinergic drugs, but by the
neurotransmitters norepinephrine (NE) and gamma-aminobutyric acid
(GABA)
.
These studies taken together provide evidence for 5-HT
and other neurotransmitter receptors in the hypothalamus which
regulate CRH release, and suggest, at least under the specified
in vitro conditions, that 5-HT functions to stimulate CRH
secretion.
Studies on the effect of 5-HT and 5-HT altering drugs on HP
A
hormone secretion in unstimulated animals
.
5-HT administration
. The effect of intracranial injections
on pituitary-adrenal activity has been studied in several species.
Krieger and Krieger (1970) observed a stimulation of pituitary
adrenocortical activity with intraventricular injections of 5-HT
in cats. In guinea pigs, 5-HT injections into several brain areas
elevated plasma 17-hydroxycorticosteroids in both intact animals
and in those which had received midbrain transections (Naumenko,
1968) . This latter result indicated that 5-HT induced HPA stim-
ulation does not involve ascending pathways below the level of the
transection.
In a subsequent study, the same investigator (Naumenko,
1969) showed that 5-HT injections into different brain regions
may cause differences in HPA functioning. In this study, a rise
in plasma corticosteroids was seen in response to 5-HT injections
to the ventral hippocampus, while 5-HT administered to the dorsal
hippocampus produced a 20% decrease in plasma 17-hydroxycorticos-
teroids. Similarly, an increase in corticosteroids was seen when
5-HT was injected into the septum while a decrease was seen in
the amygdala. The results of this study suggest that different
5-HT pathways may act in a different capacity to mediate pituitary-
adrenocortical activity. This is consistent with the idea of
independent neural inputs regulating HPA activity.
Vermes and Telegdy (1972) showed that 5-HT intraventricular
injections had no effect on pituitary-adrenal activity in rats.
It is therefore difficult to draw firm conclusions from these
studies, however the majority are consistent with the in vitro
experiments which support a primary stimulatory role for 5-HT in
HPA hormone secretion.
Administration of 5-HT precursors
.
L-5-hydroxytryptophan
(5-HTP) is the immediate precursor to 5-HT and has been used to
study the involvement of 5-HT in pituitary-adrenal functioning.
In rodents doses of 50 mg/kg (Fuller, Snoddy & Molloy, 1976;
Meyer, Buckholtz & Boggan, 1978) to 100 mg/kg (Popova, Maslova &
Naumenko, 1972) 5-HTP produced elevations in circulating corticos-
teroids. This effect was potentiated by a monoamine oxidase (MAO)
inhibitor (a drug which prevents the degredation of 5-HT and
catecholamines into their precursors by the enzyme MAO) (Fuller &
Clemens, 1981). This suggests a hormone elevation due to 5-HT,
7but does not rule out the possibility of an involvement of other
monoamines such as NE and dopamine (DA), since MAO inhibition may
have an effect on the release of these neurotransmitters.
Fluoxetine, a 5-HT reputake inhibitor significantly poten-
tiated the 5-HTP induced rise in circulating corticosterone
(Fuller, Snoddy, & Molloy, 1976). This clearly suggests a hormone
elevation due to serotonergic activity. Attempts have also been
made to attenuate the increase in corticosterone seen with 5-HTP.
Meyer, Buckholtz and Boggan (1978) found that metergoline and
cyproheptadine antagonized the effect of 5-HTP in mice. Steiner
and Grahame-Smith (1979) found no effect with those particular 5-HT
receptor blockers in rats, but did see an antagonism of the 5-HTP
effect using mianserin, a less potent receptor blocker which may
be acting at a different 5-HT receptor site. Meyer and co-workers
also found that the 5-HTP effect was significantly attenuated by
peripheral decarboxylase inhibitors in rats (submitted for pub-
lication) and mice (1978), but others have not been able to rep-
licate these findings (Fuller, 1981; Steiner & Grahame-Smith,
1979). In general, the success of 5-HT agents in altering the
corticosteroid response to 5-HTP suggests a 5-HT involvement in
pituitary-adrenal hormone regulation. One problem in using this
precursor, however, is that the enzyme which converts 5-HTP to
5-HT is nonspecific and is found in other neurons, particularly
catecholaminergic ones. Therefore, administration of 5-HTP can
result in 5-HT production in brain areas that don't usually
8contain 5-HT. This means that corticosterone changes in response
to 5-HTP do not necessarily reflect the normal physiology of sero-
tonergic HPA regulation.
For this reason, some experimentors argue that it is more
desirable to use the dietary precursor of 5-HT, tryptophan.
Studies of L-tryptophan administration in man have been somewhat
successful in demonstrating a role for 5-HT in HPA hormone reg-
ulation but the nature of this role remains obscure: Imura, Nakai
and Yashimi (1973) demonstrated that tryptophan at a high
dose (150 mg/kg) increases pituitary-adrenal activity, while Woolf
and Lee (1977) showed that tryptophan produced a decrease in base-
line Cortisol levels at the low dose of 20 mg/kg.
In animals it has been necessary to give very high doses of
tryptophan to obtain a rise in corticosterone since only a small
percentage of peripherally injected tryptophan enters the brain
(Fuller, 1981). However, investigators have not been able to po-
tentiate this response with fluoxetine or attentuate it with p-
chlorophenylalanine (PCPA) , a potent 5-HT depleter (Fuller, 1980).
Thus, it is unclear whether the effect of very high doses of
tryptophan in elevating circulating corticosteroids is serotonergic-
ally mediated. It is unfortunate that there are so many method-
ological limitations in using 5-HT precursors to ascertain the role
of 5-HT in HPA hormone regulation; other 5-HT pharmacological
manipulations which have been free from these particular problems
have been able to address this issue more clearly.
Effect of serotonergic drugs. Quipazine, a direct receptor
stimulant caused dose-dependent increases in circulating cor-
ticosterone in rats (Fuller, Snoddy & Clemens, 1978) and mice
(Meyer, Buckholtz & Boggan, 1978). This effect was antagonized
by metergollne in rats (Fuller & Snoddy, 1979), but not in mice
(Meyer, Buckholtz & Boggan, 1978). The quipazine induced rise in
corticosterone was still seen in rats pretreated with 5,7-DHT
(Fuller, 1981). This result was expected, as quipazine acts on
post-synaptic 5-HT receptors.
The 5-HT releasers fenfluramine and p-chloramphetamine (PCA)
also increased levels of corticosteroids (Fuller & Snoddy, 1980).
The effect of PCA was prevented by PCPA pretreatment , and also by
fluoxetine (Fuller & Snoddy, 1980). PCPA depletes neurons of 5-HT
making small amounts of this neurotransmitter available for
release. Fluoxetine inhibited the uptake of PCA into serotonergic
neurons, making them unable to affect 5-HT release.
Fluoxetine also elevated levels of corticosterone (Fuller,
Snoddy & Molloy, 1976), presumably by maintaining elevated levels
of 5-HT in the synapse and causing increased stimulation of post-
synaptic neurons.
Despite the rise in corticosterone seen with serotonergic
agonists, antagonists such as receptor blockers, depleters and
neurotoxins have not been able to lower baseline corticosterone
levels. They have only been able to in some cases antagonize the
elevation of corticosteroids in response to agonists. In fact,
10
Meyer et al. (1978) have found that cyproheptadine and metergoline
alone actually elevated corticosterone levels in mice.
That 5-HT antagonists attenuate corticosterone responses only
in a state of hormone elevation suggests that the HPA system may
respond differently to neurotransmitters, particularly 5-HT, in
different ways depending on the system's level of excitation. If
this is true, 5-HT may mediate hormone secretion differently in
response to stress, or under conditions where the pituitary-adreno-
cortical system is stimulated. The next section will review the
pharmacological data on the effect of 5-HT in stimulated animals,
and will pay particular attention to its inconsistencies with the
aforement ioned
.
Effect of 5-HT and 5-HT altering drugs under conditions where the
HPA system has been stimulated
. The results of studies using
stressful manipulations or other situations in which baseline
pituitary-adrenal activity is elevated have been difficult to
interpret for several reasons. The primary one seems to be the
lack of consistency between data obtained in human and animal
studies
.
Human studies
. In general, human studies have been consis-
tent with each other, and with both the in vitro studies and
studies of unstimulated organisms. In most cases, results have
confirmed a stimulatory role for 5-HT. For example, the 5-HT
receptor blocker metergoline reduced increased ACTH levels seen
in response to insulin stress (Cavagnini et al., 1976).
11
In other situations (which are not accurately considered
stress-induced) where the HPA system is stimulated, other 5-HT
antagonists have produced similar effects. In addition to meter-
goline, methysergide (Cavagnini et al.
,
1975) and cyproheptadine
(Plonk & Feldman, 1976) were effective in lowering increased
ACTH levels following metyrapone treatment. (Metyrapone is an
adrenocortical antagonist which interferes with the synthesis of
corticosteroids, and as such eliminates feedback inhibition of
corticosteroids on ACTH. This drug is often used to determine
whether hypersecretion of corticosteroids is due to adrenal tumors
or pituitary malfunctions.)
Cyproheptadine was also effective in reducing symptoms of
two clinical endocrinopathies, Cushing's disease, which is char-
acterized by adrenocortical hypersecretion (Krieger, Amorosa &
Linisk, 1975), and Nelson's syndrome, in which excessive ACTH
secretion occurs as a result of bilateral adrenalectomy treatment
in Cushing f s patients (Krieger & Luria, 1976). These studies are
consistent with the idea that the role of 5-HT in the adreno-
cortical response to stress is stimulatory.
Animal studies . Results obtained from animal studies have
not been consistent with the human data. Some investigators have
reported inhibitory effects of 5-HT on the pituitary-adrenal
response to stress. In rats, for example, the increase in cir-
culating ACTH levels produced by ether was blocked by pretreat-
ment with tryptophan, and enhanced by PCPA (Vernikos-Danellis &
12
Berger, 1973). Intraventricular injection of 5-HT (while reported
by these investigators to have no effect on baseline HPA secre-
tion) prevented the corticosterone increase in response to surgical
stress (Telegdy & Vermes, 1976).
Other investigators, however, have failed to alter the
adrenocortical response to stress using serotonergic drugs. The
5-HT reuptake inhibitor fluoxetine did not influence plasma cor-
ticosterone levels following either swim stress or insulin stress
(Fuller & Snoddy, 1977). PCPA had no effect on increased plasma
corticosterone levels seen with hypoxia (oxygen deprivation) or
hypercapnia (oxygen deprivation 4- carbon dioxide administration)
(Marotta et al., 1976), while 5-HT depletion produced by the
neurotoxin 5,7-DHT or electrolytic lesions of the midbrain raphe
did not alter the ACTH response to ether (Karteszi, 1981).
It would be tempting at this point in the discussion to
simply conclude that 5-HT stimulates the pituitary-adrenal system
in animals at a baseline hormone level, and inhibits or has no
effect on HPA hormones in response to stress. Unfortunately,
studies of the effect of 5-HT on animals in response to stress are
contradictory, since some studies fail to find any role for 5-HT.
Before accepting the aforementioned conclusion it is necessary to
further investigate the effect of 5-HT manipulations on pituitary-
adrenal hormones in response to stress.
With respect to the disparity between studies of stimulated
humans and animals it appears that 5-HT regulation may function
13
in a different manner in man and rodents. Ordinarily, this would
be an acceptable conclusion, however, we shall now look at studies
on the effect of stress on 5-HT metabolism in animals which in-
dicate a role for 5-HT which is quite in contradiction with the
pharmacological studies which have just been discussed.
The effect of stress on 5-HT bra in metabolism
. Investigators have
taken two basic approaches to measure the effect of stress on
brain 5-HT. One method, used particularly in the earlier studies,
has been to administer a stressor to an animal, and then simply
measure the content of this neurotransmitter in either the whole
brain or various parts of the brain. In these studies, elevated
levels of 5-HT were seen as an indication of increased 5-HT
synthesis. Many of these studies showed that stress had no
effect on 5-HT, and concluded, therefore, that this neurotrans-
mitter was not involved in the regulation of the stress response.
Some investigators, however did see increased concentrations of
5-HT with stress. De Schaapdryver
, Preziosi and Scapagnini (1969),
for example, observed a 10% increase in whole brain 5-HT (and a
simultaneous drop in NE and DA)
.
In 1966, a more sophisticated method of looking at 5-HT
metabolism was described by Tozer, Neff and Brodie (1966) . This
method is based on assuming a steady state kinetics of the 5-HT
system. That is, the rate at which tryptophan and 5-HT are con-
verted to 5-HT is considered to be equal to the rate of conversion
14
of 5-HT to its metabolite 5-HIAA. This situation is characterized
as an open system; under these conditions the level of brain 5-HT
remains constant and the rate of formation of 5-HT is equal to the
rate of turnover. Investigators can estimate the rate of 5-HT
synthesis by pharmacologically preventing the conversion of 5-HT
to its metabolite 5-HIAA and measuring the (exponential) decline
of 5-HIAA. By plotting the logarithms of 5-HIAA .concentrations at
various time points and using the slope of the line to determine a
rate constant, one could express the rate at which 5-HT has been
synthesized (i.e., turnover) from the product of the rate constant
of 5-HIAA decline and the normal 5-HIAA level. Alternatively,
one can measure the accumulation of 5-HT after inhibiting the
formation of 5-HT to 5-HIAA (Neff & Tozer, 1968). After such
treatment 5-HT will accumulate in the brain at a rate proportional
to its synthesis. This method is based on assuming a lack of feed-
back inhibition on tryptophan hydroxylase by 5-HT.
Bliss, Thatcher and Ailion (1972) looked at several types of
stressors and their effect on 5-HT content and turnover. There
was no change reported in 5-HT content with foot shock in mice or
rats, but increased 5-HT turnover was seen in whole brain. The
lack of altered 5-HT content was interpreted by Bliss, Thatcher
and Ailion to mean that brain levels of 5-HT remain stable even
during increased 5-HT synthesis, a phenomenon which may explain
the failure of some investigators to observe changes in 5-HT con-
tent. Increased 5-HT turnover was also seen during sleep
15
deprivation stress, swim stress, and psychosocial stress, which
involved exposing rat colonies to different strains of rats in
a noval environment.
Increased 5-HT turnover in response to stress was also ob-
served by several other investigators. Increased rates of 5-HT
turnover during restraint stress have been observed in whole brain
(Kenneth & Joseph, 1982), in the cerebral cortex (Morgan, Rudeen
& Pfeil, 1975) and in the hypothalamus (Mueller et ai.
,
1976).
Food deprivation and novelty stress also increased whole brain
turnover (Curzon, Joseph & Knott, 1972; Knott, Joseph & Curzon,
1973; Knott, Hutson & Curzon, 1977).
The different methodological approaches discussed earlier
which attempted to determine the role of 5-HT in stress met with
contradictory results. This line of research is no exception.
While the above studies are clearly consistent with a stimulatory
role for 5-HT in pituitary-adrenocortical function in response to
stress in rats, other experiments have produced data leading to an
opposite conclusion.
Telegdy and Vermes (1976) tested many types of stressors for
their effect on 5-HT turnover in brain hypothalami. Some stressors,
like cold stress, restraint or two minute exposure to ether caused
rapid changes in both corticosterone levels reaching a peak, and
5-HT levels reaching a maximum descent at 30 minutes. By 90
minutes following stress onset, levels of 5-HT started to ascend,
ultimately overshooting baseline levels. Other stressors such as
16
electric shock or surgical stress produced corticosteroid responses
which remained high even 90 minutes after the onset of stress, al-
though levels of 5-HT, which were initially decreased, returned to
normal by that time. A third type of stressor, such as formalin
stress, produced low hypothalamic 5-HT levels and high corticos-
terone concentrations which lasted beyond 90 minutes. This study
suggests that the very nature of the stressor may affect the involve
ment of 5-HT in hormone regulation.
The depletion of 5-HT seen when HPA hormone levels are
elevated suggests an inhibitory role for 5-HT. According to
Telegdy and Vermes, under normal conditions 5-HT exerts an in-
hibition on the hypothalamus, causing low baseline corticosterone
levels. During stress, 5-HT is depleted, and inhibition is re-
moved, thus increasing corticosterone plasma concentrations. The
model further proposes that the elevated levels of corticosterone
subsequently restore the depleted hypothalamic 5-HT. When 5-HT
levels, and therefore, the inhibition due to 5-HT are restored,
corticosterone levels return to their low baseline levels. To lend
further support to this theory, the authors administered 1 mg/kg
i.p. corticosterone to rats and found a rapid increase in 5-HT
concentrations in the hypothalamus, mesencephalon and amygdala.
Administration of 20 yg 5-HT intraventricularly diminished the
rise in plasma corticosterone seen in response to surgical stress.
It is difficult, indeed, to account for the contradictory
results seen in these experiments. What these inconsistencies
17
suggest, however, is that determining a role for 5-HT is perhaps
more complicated than simply deciding between its actions as an
inhibitory or an excitatory neurotransmitter in response to
stress. One approach to take in explaining some of the in-
consistencies is to point out that scientists have been at some-
what of a disadvantage in their studies since 5-HT pharmacology is
not as far advanced as the pharmacology of certain other trans-
mitters such as the catecholamines.
Part of the lack of knowledge regarding 5-HT pharmacology is
directly related to an incomplete understanding of 5-HT receptors.
The existence of multiple 5-HT receptors in brain was suggested
as early as 1967 by studies in the cerebral cortex, where micro-
iontophoretically applied 5-HT produced either excitation or in-
hibition in some neurons (Roberts & Straughan, 1967). Recent
data suggests that there are at least three different types of
5-HT receptors in the brain (Aghajanian, 1981). Two 5-HT recep-
tors are post-synaptic; one type is thought to be excitatory
(Type 2) while the other suppresses neuronal activity (Type 1).
Located presynaptically are 5-HT autoreceptors which mediate 5-HT
inhibition. Different drugs may act selectively at these different
5-HT receptor sites, but these interactions are not fully under-
stood. In addition, it is not clear whether 5-HT receptor types
mediate different actions of 5-HT in response to stress.
It is also necessary to point out that the range of
methodological techniques which have been used in various studies
18
has made it more difficult for researchers to obtain similar
results. For example, in turnover studies, experimenters have
not consistently looked in the same brain regions. In pharma-
cological studies, investigators have not always used the same
drugs to alter HPA hormone secretion. In stress studies, dif-
ferent stressors have been used. This latter factor may particu-
larly account for much of the variability in the data since
different types of stressors influence 5-HT differently, and 5-HT
may act in a different capacity in response to different stressors.
Another important factor to consider is that many studies
have suggested an involvement of other neurotransmitters either
directly or indirectly by virtue of a failure of serotonergic
manipulations to influence pituitary-adrenal activity. Given the
complexity of interaction between neurotransmitters, it is expected
that some contradictions will arise. Certainly it is important to
consider how other neurotransmitters may affect HPA hormone secre-
tion. Some of the aforementioned studies have indicated a -
cholinergic involvement in HPA regulation. There has also been
increasing evidence for the involvement of catecholarainergic
systems
.
Interactions of catecholaminergic neurotransmitters . Administration
of the DA agonist pergolide, elevated serum corticosterone concen-
trations in rats (Fuller & Snoddy, 1981). Such stimulation was
prevented by pretreatment with DA antagonists. Intravenous
19
administration of the DA precursor L-dopa similarly elevated levels
of Cortisol in humans (Wilcox et al., 1975). On the other hand,
i.v. pulse injections of the DA blocker haloperidol enhanced
resting plasma Cortisol levels (Balestreri, Bertolini, and Castello,
1979), a result consistent with the effect of L-dopa in atten-
uating the plasma Cortisol response to insulin-induced hypo-
glycemia seen by the same investigators. Although these latter
results suggest an inhibition by DA of pituitary-adrenocortical
hormone secretion, the authors suggest that haloperidol may be
acting on DA postsynaptic (self-inhibiting) neurons, and therefore
may actually be increasing DA synthesis. Thus, it is not completely
clear what the action of DA may be in CRH regulation.
Studies on the effect of NE have been somewhat less ambiguous
and have shown that NE acts to inhibit CRH-ACTH secretion. For
example, large doses of NE have been found to prevent the increase
in ACTH normally seen in response to surgical stress (Van Loon
et al., 1971). NE antagonists such as reserpine, a NE depleter
(Scapagnini et al., 1972) and alpha
-methyl-p-tyrosine, an NE
synthesis inhibitor (Van Loon et al., 1971) seem to enhance stress-
induced ACTH secretion.
These are just a few studies which indicate an involvement of
catecholamines in HPA regulation of hormone secretion. Here too,
it is unclear to what extent and in what capacity, these neuro-
transmitters are acting. In many studies, catecholamines exert
direct action on HPA hormone secretion, however, in addition to
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this direct effect, these neurotransmitters may exert action on
5-HT which could directly affect 5-HT regulation of HPA functioning
Scope and purpose. Despite the fact that studies concerning the
neural regulation of stress continue to accumulate, there is no
clear picture of the factors which regulate HPA hormone secretion
in response to stress. Even the experimenters who have inves-
tigated a role for 5-HT in the regulation of this axis are still
in debate over whether 5-HT acts to stimulate or to suppress this
axis. In view of the controversial results cited above, the
following experiments were performed in an attempt to clarify the
role of 5-HT in the pituitary-adrenal response to stress. The
stress of insulin-induced hypoglycemia was chosen because this
stressor is easily quantified and manipulated, it represents a
physiological challenge to the organism, and the stress response
can (through measurements of blood glucose) be assessed indepen-
dently of pituitary-adrenal activity.
CHAPTER II
METHODS AND MATERIALS
General methods
.
Two hundred twenty six adult male Wistar rats
were purchased from Charles River or bred in our laboratory.
Animals were housed singly in a colony room under a 14:10 light-
dark cycle (lights on at 0600 hours) and were fed Purina lab chow
and tap water ad libitum
. The rats weighed 225-350 g at the time
of experimentation.
All experiments took place between 0800 and 1100 hours when
the serum corticosterone concentration is low in the normal
diurnal rhythm. All animals were fasted approximately 16 hours
before receiving insulin or vehicle. At the appropriate time
after drug administration, animals were quietly removed from the
colony room and killed by decapitation at intervals of at least
2 minutes. Trunk bloods were collected and allowed to clot on
ice. Bloods were then centrifuged and the sera aspirated and
frozen at -40°C for corticosterone determination by radioimmuno-
assay. In some cases, serum glucose analyses or hypothalamic 5-HT
determinations were also performed.
Experiment I: Characterization of the corticosterone and glucose
response to insulin stress
.
Dose-response and time-course studies
were carried out in order to determine the parameters of both the
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corticosterone response to insulin and the corresponding glucose
levels. In the dose-response study, fasted rats were injected
subcutaneously (s.c.) with one of 5 doses of insulin (Squibb,
UAO) ranging from 0.125-.250 U/kg or saline, and were killed 40
minutes later.
For the time-course study, fasted rats were killed 0, 20,
40, 60, and 80 minutes after the s.c. injection of .20 U/kg
insulin or saline. In both cases, serum corticosterone and
glucose were analyzed.
Experiment II: The effect of insulin stress on hypothalamic 5-HT
turnover
.
Changes in 5-HT turnover after insulin or saline were
measured in order to determine whether the metabolism of this
neurotransmitter is altered in response to stress. Turnover was
measured by preventing the degradation of 5-HT into 5-HIAA and
allowing 5-HT to accumulate in the hypothalamus. This method is
similar to that of Tozer and Neff (1968) and is based on assuming
a lack of feedback inhibition by 5-HT on tryptophan hydroxylase,
the enzyme which converts tryptophan to 5-HTP.
In this experiment, MAO was inactivated with pargyline.
Fasted animals were injected intraperitoneally (i.p.) with 75 mg/kg
pargyline (Sigma Chemical Co.) and then 5 minutes later either
killed immediately or injected with 0.20 U/kg insulin or saline.
The latter two groups were killed 45 minutes after pargyline
administration. 5-HT turnover was measured by the accumulation of
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5-HT as a result of the pargyline treatment. Hypothalamic 5-HT
concentrations were determined in all animals by the method des-
cribed below.
Experiment III: The effec t of physiological serotonerg ic
manipulations on the corticosterone response to insulin strPRfi .
It was of interest to determine whether the rise in corticos-
terone associated with insulin stress is a result of increased
availability of the 5-HT precursor tryptophan to the brain. In
this study the normal plasma concentrations of tryptophan and
another amimo acid, namely valine, were altered. Valine is a
neutral amino acid that has previously been shown to compete with
tryptophan for entrance across the blood-brain barrier (Pardridge,
1979)
.
The administration of tryptophan and valine are in a sense
physiological serotonergic manipulations because of their poten-
tial ability to alter the availability of tryptophan, and there-
fore, of 5-HT synthesis.
In the first part of this study, L-tryptophan (Sigma Chemical
Co.) was tested for its ability to potentiate the effect of a
submaximal dose of insulin on circulating corticosterone levels.
Fasted animals were pretreated s.c. with 200 mg/kg tryptophan
20 minutes before receiving 0.150 U/kg insulin or saline. Next,
animals were pretreated s.c. with 200 mg/kg valine 20 minutes
before receiving 0.20 U/kg insulin or saline. Blood samples were
obtained in the usual manner 40 minutes following insulin
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treatment
Experiment IV: The effect of pharmacological manipulations onj^
corticosterone response to insulin stress . Two pharmacological
manipulations were employed to investigate the effect of 5-HT
antagonism on the corticosterone response to insulin. The first
study attempted to determine whether the insulin
-induced rise
in corticosterone could be attenuated with a drug that blocks
serotonergic action. Fasted animals were pretreated i.p. with
5 mg/kg methysergide (Sandoz
,
Inc.) a serotonergic receptor
blocker, 1 hour before receiving 0.20 U/kg insulin or saline.
Animals were killed AO minutes following this latter injection.
Next, brain 5-HT was depleted using the potent 5-HT neuro-
toxin 5,7-DHT (Sigma Chemical Co.). 5,7-DHT decreases brain
5-HT by about 70-80% when measured 8-12 days after administration
(Baumgarten et al., 1975). Rats were anesthetized with Equithesin
(Jensen Salsber Laboratories), placed in a stereotaxic instrument,
and then injected intraventricularly with 150 yg of 5,7-DHT (free
base) in 20 yl of 0.1% ascorbic acid. Control animals received
an equal volume of the ascorbic acid alone. Because 5,7-DHT
can also produce a moderate depletion of brain NE, animals were
pretreated i.p. with 25 mg/kg desipramine (Merrel Dow Research)
45 minutes before drug or vehicle injections. Desipramine is a
potent inhibitor of NE uptake, and therefore prevents 5,7-DHT
from entering noradrenergic neurons (Bjorklund, Baumgarten &
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Rensch, 1975). Ten days later, fasted animals were killed 40
minutes following the injection of 0.20 U/kg insulin or saline.
Blood samples were collected for subsequent corticosterone deter-
mination and hypothalami dissected and assayed for their 5-HT
content
.
Serotonin determination. Following decapitation, brains were re-
moved and hypothalami were rapidly dissected over ice. A rostral
coronal cut was made from the ventral side of the brain at the
level of the suprachiasmatic nuclei, and a caudal transection was
made immediately posterior to the mammillary bodies at the level
of the interpeduncular fossa. The hypothalamus was removed from
its lateral boundaries, the entorhinal cortex, with two 5 mm
cuts. A final horizontal cut separated the hypothalamus from the
overlying thalamus. Each hypothalamus was weighed, and then
homogenized in a total volume of 2 . 0 ml of ice-cold .AN HCIO4 to
deproteinize the tissue. In addition, 50 yl of 10% disodium
ethylenediamine tetra-acetate (EDTA) was added to the HCIO4 to
chelate any contaminating heavy metals during homogenization, and
50 yl ascorbic acid was added to protect the 5-HT during extrac-
tion. Samples were centrifuged at
-5°C for 20 minutes at
30,000 x g. Supernatants were decanted and were then brought up
to a pH of 5.5-6.0 using KOH. One drop of 0.04% bromphenol blue
in absolute ethanol was added to each tube to aid in the pH
adjustment. Samples were recentrifuged for 5 minutes to remove
the KC104 precipitate. Supernatants were decanted and brought to
room temperature, and were applied to 3 x 20 mm columns of a weak
cation exchange resin (Bio-Rex 70, Bio-Rad Laboratories) which had
been cycled according to the manufacturer and then equilibrated
in a 0.1M sodium phosphate buffer, pH 6.5, containing 0.1% di-
sodium EDTA (Barches, Erdelyi & Angwin, 1972). The columns were
washed first with 1.5 ml 0.02 M phosphate buffer, pH 6.5 con-
taining 0.2% disodium EDTA, and then with 1.0 ml deionized water,
as described by Holman, Angwin and Barchas (1970). 5-HT was
eluted with two 0.5 ml aliquots of 2.5 N HC1, most of the 5-HT
being recovered in the first eluate. Each 5-HT eluate was reacted
with o-pthalaldehyde (OPT, Sigma Co.) (Maikel & Miller, 1966)
which had been repurified in our laboratory according to Jacobowitz
and Richardson (1978). Stock solutions of 0.5 mg/ml OPT were made
weekly and stored at 4°C. On the day of each assay, a portion of
this solution was diluted 1:19 in concentrated HC1 to yield a
working acidified OPT reagent. For the standards, a stock solution
of 5-HT creatinine sulfate (Regis Chemical Co.) corresponding to
1.0 mg/ml free 5-HT was made up in 0.01 N HC1 and stored at 4°C
for up to 1 month. A standard curve was constructed for each assay
by diluting the stock 5-HT solution in 2.5 N HC1 to a final con-
centration of 900 ng/ml. Appropriate volumes yielding 9-67.5 ng
5-HT were placed in assay tubes and were then reacted with the
acidified OPT reagent. Samples and standards were heated at
100°C for 10 minutes, cooled to room temperature, and then read
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on a Perkin-Elmer #1000 Spectrofluorometer at (uncorrected) ex-
citation and emission wavelengths of 364 nm and 480 nm respec-
tively. Unknowns were calculated from the standards using a
least squares linear regression.
Rad io immunoassay. For thp Hpt-prminaHA^ ~cru ne de ermination of serum corticosterone,
each frozen serum sample was thawed and diluted 1:99 in 0.65 M
sodium buffer, pH 8.0. Samples were heated at 75°C for 30
minutes to denature transcortin, an endogenous corticosterone
binding globulin, and were then allowed to cool to room temperature
For the preparation of standards, unlabeled corticosterone
(Steraloids, Inc.) was dissolved in absolute ethanol, and appro-
priate volumes yielding 20, 50, 100, 200, 500 and 1000 pg
corticosterone were placed in clean assay tubes. Standards were
then evaporated under N2 and redissolved in 50 ul borate buffer.
The RIA utilized a H-cort icosterone tracer (92.0 Ci/mmol,
New England Nuclear) and an anticorticosterone antiserum (B3-163,
3Endocrine Sciences). H-corticosterone was diluted in absolute
ethanol, stored at -10°C, and periodically repurified by Sephadex
LH-20 column chromotography (Murphy & Diez D'Aux, 1975). The
anticorticosterone antiserum was found to cross-react 0.4% with
Cortisol (based on 100% reactivity with authentic corticosterone)
4.9% with deoxycorticosterone, 0.7% with progesterone, and less
than 0.1% with both testosterone and estradiol. The tracer-
antiserum mixture was prepared in a sodium borate buffer containing
0.2% bovine serum albumin (Sigma Co.) and 0.05% bovine gamma
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globulin (BGG) (Sigma Co.). BGG was added to increase the mass of
precipitated protein in the ammonium sulfate step described below.
Two hundred yl of the trace-ant iserum mixture was reacted
with 50 ul aliquots of the heat-denatured samples and standards
(in duplicate)
.
Each tube contained approximately 6000-7000 CPM
of H-corticosterone and a final antiserum dilution of 1:1500.
Tubes were incubated for 2 hours at room temperature, and were then
precipitated with 250 yl of saturated ammonium sulfate. Samples
were centrifuged for 10 minutes at 2,800 RPM (room temperature),
and the supernatant containing the unbound corticosterone was
decanted into a scintillation vial with 10 ml of a toluene-based
cocktail containing 4.0 g PPO and 0.1 g bis-MSB per 1. The
pellets containing the precipitated antibody were discarded.
The unbound H-corticosterone was allowed to partition into
the toluene phase overnight, and was read the next morning on a
Packard Tri-Carb #2425 scintillation counter. The data were sub-
jected to log-logit transformations. Unknowns were calculated
from the standards using least squares linear regression. Each
assay included a quality control sample from a serum pool containing
approximately 32.5 yg of corticosterone per 100 ml. The interassay
coefficient of variation calculated from these samples was 15.8%.
Glucose analysis . Serum glucose was analyzed by the glucose
oxidase method using kit //510A purchased from Sigma Co. In this
procedure, a solution containing horseradish peroxidase and glucose
oxidase was added to diluted aliquots of serum. Glucose oxidase
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was used to convert glucose to gluconic acid, yielding hydrogen
peroxide as a by product. The horseradish peroxidase and a
color reagent, o-dianisidine dihydrochloride were then allowed
to react with the peroxide for 30 minutes at 37°C, yielding a
brown product, oxidized o-dianisidine. The intensity of the
brown color as measured at 450 nm on a Bausch and Lomb #88 spec-
trophotometer was proportional to the original glucose concentration
A stock solution of 100 mg/dl beta-D-glucose in 0.1% benzoic acid
was provided with the kit and stored at 4°C. Standards of 50-
300 mg/dl were diluted in deionized water for use in the first of
these assays and standards of 50-100 mg/dl were used in each sub-
sequent assay. Unknowns were calculated from the standards using
linear regression.
Data analysis
.
All data were subjected to analyses of variance
(ANOVA) followed by individual mean comparisons using Fischer's
Least Significant Difference Test (Kirk, 1968). Data from the
turnover study were evaluated using a Student's t-test. Results
occuring with a chance probability of less than .05 were considered
statistically significant.
CHAPTER III
RESULTS
Experiment I
.
The effect of differing doses of insulin on serum
corticosterone and glucose concentrations is shown in Fig. 1.
Insulin significantly elevated serum corticosterone (F5 25 - 28.51)
and lowered glucose levels (F5)2 4 " 4.49) in a dose-dependent
manner at all doses except the lowest one, .125 U/kg. The time-
course of these responses to insulin is shown in Fig. 2. Serum
corticosterone reached a maximum at 40 minutes and began to de-
crease by 60 minutes. Post hoc testing revealed that all groups
of insulin treated animals were significantly higher than saline
controls (F1>40 =- 64.04) except at the 20 minute time point.
Glucose levels in the insulin treated animals were found to be
different than saline controls at all times (F^q = 151.61; Fig. 3).
Experiment II
. The effect of insulin on hypothalamic 5-HT turnover
can be seen in Fig. 4. The pargyline induced accumulation of 5-HT
40 minutes following insulin administration was significantly
higher than its accumulation following saline (t lg = 2.67). This
indicates an increased rate of hypothalamic 5-HT synthesis (turnover)
as a result of insulin stress.
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Dose of Insulin U/kg
Fig. 1. Dose-dependent changes in serum corticosterone and
glucose concentrations following insulin. Insulin was injected
s.c. at the doses indicated, 40 min before the animals were
decapitated. Each value shown is the mean ± SEM for 5 rats
per group.
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Fig. 2. Time-course effect of insulin on serum corticoster
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AUerin§ P 1— amino acid concentrations pro-
duced substantial changes in the corticosterone response to
insulin stress. First, the effect of tryptophan on a submaximal
dose of insulin was investigated. An initial ANOVA performed on
the data yielded significant main effects for both the treatment
(F1>32 = 13.08) variables. Rats given 0.150 U/kg of insulin
had higher overall corticosterone levels than their saline-
injected counterparts, while tryptophan pretreatment potentiated
the responses to both insulin and saline (Fig. 5).
The effect of valine on the corticosterone response to a
higher dose of insulin is illustrated in Fig. 6. In this case,
an overall ANOVA on the results revealed a significant inter-
action between treatment with insulin and pretreatment with
valine (F1>2Q =7.70). It can be seen that although 200 mg/kg
valine did not alter serum corticosterone in saline-injected rats
the same dose almost completely prevented the stress-induced in-
crease in corticosterone observed following insulin. Post hoc
testing confirmed that the valine-insulin animals were signif-
icantly different from the saline-insulin animals, but did not
differ from either control group. These findings are consistent
with the idea that tryptophan availability plays an important rol
in the pituitary adrenal response to insulin-induced hypoglycemia
Experiment IV . Treatment with methysergide reduced levels of
circulating corticosterone in both insulin and saline treated
animals (F1>2 7 =7.78). As illustrated in Fig. 7, the effect of
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Fig. 5. Effect of tryptophan pretreatment on serum
corticosterone response to insulin stress. A dose of
0.15 U/kg insulin or saline was injected s.c. 40 min
before rats were killed and 20 min after the s.c. injec-
tion of 200 mg/kg L-tryptophan. Values represent the
mean ± SEM for 9 rats per group.
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Fig. 6. Effect of valine pretreatment on serum cort-
icosterone response to insulin stress. A dose of 0.20 U/kg
insulin or saline was injected s.c. 40 min before rats
were killed and 20 min after the s.c. injection of 200
mg/kg valine. Values represent the mean ± SEM for 6 rats
per group.
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Fig. 7. Effect of methysergide on the serum cor-
ticosterone response to insulin stress. Rats were pre-
treated with 5 mg/kg methysergide i.p. 1 h before re-
ceiving 0.20 U/kg insulin or saline and killed 40 min
later. Values represent the mean ± SEM for 8 rats in
all groups except the methysergide-insulin group, in
which n = 7.
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methysergide was of greater magnitude in the saline-treated con-
trols.. It should be noted that these controls have been subjected
to two mild stressors, namely i.p. injection and 16 hour food
deprivation. Thus, methysergide (at the present dose) was capable
of inhibiting pituitary-adrenal responses to stress, but a
smaller degree of inhibition was observed when the stress was more
potent
.
Hypothalamic 5-HT content was depleted by an average of 75%
when measured 10 days after treatment with 5,7-DHT (mean hypo-
thalamic 5-HT content =0.19 yg/g tissue compared to 0.76 yg/g
in sham operated animals) (Fig. 8). Analysis of the corticoster-
one data revealed a main effect for insulin treatment (F, 9 =
36.25) and a significant interaction between insulin and 5,7-DHT
( Fl,20 = 1:L - 62 )- Post hoc testing showed that 5,7-DHT significantly
lowered the insulin-induced elevation of serum corticosterone
(Fig. 9).
Fig. 8. Effect of 5,7-DHT on hypothalamic 5-HT
content 10 days after the intraventricular injection
150 yg 5,7-DHT in 0.1% ascorbic acid or vehicle alone
Values represent the mean ± SEM for 6 rats per group.
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Fig. 9. Effect of 5,7-DHT on the serum corticoster-
oid response to insulin. 150 yg 5,7-DHT in 0.5% ascorbic
acid or vehicle alone was injected intraventricularly 45
min after pretreatment with 25 mg/kg desipramine.
0.20 U/kg insulin or saline were injected 10 days later
and the rats killed 40 min following this injection.
Values represent the mean ± SEM for 6 rats per group.
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CHAPTER IV
DISCUSSION
The results of these studies support the hypothesis that 5-HT
mediates, at least in part, the hypothalamic
-pituitary-adrenal
response to insulin stress. This conclusion is based on the
increase in hypothalamic turnover observed as a result of this
stress, and on the ability of the serotonergic manipulations used
to appropriately alter these effects.
Tryptophan enhanced the pituitary-adrenal response to in-
sulin while valine reduced it. Using these amino acids as 5-HT
manipulations is based on the fact that tryptophan hydroxylase,
the rate-limiting enzyme in 5-HT synthesis is not saturated in
brain with its substrate, tryptophan (Friedman, Kappelman, &
Kaufman, 1972). Thus, 5-HT synthesis can be altered by either
increasing or decreasing the availability of tryptophan with res-
pect to the enzyme. One of the factors that influence
tryptophan availability to the brain is plasma concentrations of
large, neutral amino acids which compete with tryptophan for
transport across the blood-brain barrier (Pardridge, 1979).
Therefore, the amino acid tryptophan was administered so that its
concentration and subsequent entrance to the brain would increase.
Other animals received valine, which presumably ties up the sites
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on the carrier molecule and therefore reduces the amount of tryp-
tophan entering the brain. The increase in adrenocortical
activity seen with tryptophan, and the decrease in response to
valine pretreatment suggest that the functional response to in-
sulin was partially related to tryptophan availability.
In addition to plasma amino acid concentrations, there are
other factors which affect tryptophan availability to the brain.
One such factor appears to be the amount of free vs. total
tryptophan in plasma (Knott & Curzon, 1972). Tryptophan is the
only amino acid which is bound to albumin in plasma. Normally,
about 80-90% of total tryptophan is bound while 10-20% circulates
free (McMemory & Oncley, 1958). Tryptophan shares its binding
site with nonesterified fatty acids (NEFA) which can displace
tryptophan and therefore alter the amount of free tryptophan cir-
culating in the blood. If concentrations of NEFA increase, then
free tryptophan concentrations also increase. Fasting, for
example, increases NEFA, thereby causing increased levels of free
tryptophan (Fernstrom, 1979).
It is unclear in which circumstances and to what extent the
concentration of free (as opposed to total) tryptophan plays a
role in overall tryptophan availability to the brain. For example,
Fernstrom and Wurtman (1971) have shown an increase in both 5-HT
turnover and brain tryptophan levels in response to insulin.
Insulin causes plasma NEFA to be taken up into various peripheral
tissues. This liberates albumin binding sites in plasma, and
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therefore increases the proportion of bound to free tryptophan.
The idea that free tryptophan concentrations regulate tryptophan
availability under these conditions is inconsistent with the
increase in brain tryptophan and 5-HT seen by Fernstrom and
Wurtman, but this inconsistency can readily be explained when we
consider two other factors. First, insulin causes the peripheral
uptake of neutral amino acids as well as NEFA. Because tryptophan
is bound to albumin, it Is not particularly affected in this I
manner by insulin, and therefore, the concentration of total
tryptophan remains unchanged in comparison to the reduced plasma
concentration of competing amino acids. The second factor that
is important here is the discovery by Yuwiler et al. (1977) that
tryptophan has a higher affinity for the brain capillary amino
acid transport carrier molecule than it does for albumin. There-
fore, tryptophan, whether it is bound or free, can readily be
available for entrance to the brain. In light of this, it seems
that the most important factor regulating tryptophan availability
following insulin is the reduction of plasma amino acids which
compete with tryptophan for entrance into the brain. The relative
concentrations of free vs. total tryptophan may also be important
factors, but they probably play a more significant role in
increasing brain tryptophan in the absence of reduced plasma amino
acid levels. It is interesting to note that tryptophan also
increased the serum corticosterone concentrations in the non-
insulin controls. This increase may be due to the fasted state of
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the animals since previous studies (Meyer & Yehuda, unpublished
observations) have found no response to tryptophan alone in
nonfasted animals. The results of these experiments are con-
sistent with the idea that tryptophan availability increases in
response to insulin due to the uptake of competing amino acids
by peripheral tissues. The resultant increase in brain trypto-
phan enhances 5-HT neurotransmission thereby activating
pituitary-adrenocortical secretion.
The pharmacological studies also support a role for 5-HT in
the adrenocortical response to stress. Methysergide produced an
overall reduction in serum corticosterone concentration observed
following both the mild stress of fasting and saline injection
and the more severe stress of insulin-induced hypoglycemia.
Clearly, the effect of methysergide was more robust in reducing
corticosterone responses to the milder stress. The inability of
methysergide to show a more substantial attenuation of the
response to insulin may be due in part to the great magnitude of
the corticosterone response to this stressor.
Alternatively, one could attribute the modest attenuation by
methysergide to the action of other neurotransmitters which may
be involved in the pituitary-adrenal response to insulin stress.
Although this possibility should not be ruled out, the other
studies reported above suggest a more significant role for 5-HT.
Thus, the weak effect of methysergide in contrast to the efficacy
of the other manipulations used here may be due to the particular
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pharmacological actions of this drug. It is known, for example,
that methysergide blocks Type 2 but not Type 1 5-HT receptors
(Peroutka, Lebovitz & Snyder, 1981). As discussed in the
Introduction, Type 2 receptors mediate post-synaptic excitation
by 5-HT. The partial inhibition of pituitary-adrenal functioning
by methysergide therefore suggests the possible involvement of
this specific receptor population.
The effect of methysergide on fasted, saline treated
animals is consistent with the idea of increased 5-HT synthesis
due to tryptophan availability. In fasted animals there is an
increased concentration of free tryptophan due to the displace-
ment of tryptophan from plasma albumin binding sites by NEFA.
Since the plasma concentrations of related amino acids remain
unaltered, the increase in free tryptophan concentration becomes
an important factor in the availability of tryptophan for trans-
port into the brain and subsequent conversion to 5-HT. Thus, the
effect of methysergide on serum corticosterone following fasting
and saline administration suggests that 5-HT mediates the
pituitary-adrenal response to this stressor as well.
It was important that the insulin treated animals have
comparable blood glucose levels to ensure a consistent
corticosterone response to the treatment. Thus, it was necessary
to also impose this mild stress of fasting in the control group.
Because of this, the corticosterone levels in the control
animals do not represent baseline values, and therefore it is
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difficult to interpret the effects of pharmacological manipu-
lations that altered serum corticosterone concentrations in this
group. In an ideal situation, these drugs should additionally
be tested on nonfasted subjects to discern whether they would
also affect baseline levels in unstressed animals.
Treatment with 5,7-DHT significantly reduced the pituitary-
adrenal response to insulin, despite causing slightly increased
levels of circulating corticosterone in the saline-treated controls.
This latter result could be due to a nonspecific malaise or
weight loss produced by 5,7-DHT rather than its direct anti-
serotonergic activity in pituitary-adrenal functioning. The
effectiveness of 5,7-DHT in lowering corticosterone responses to
insulin stress suggests that this process is centrally mediated.
The specific pathways involved in stimulating pituitary-adrenal
function in response to insulin stress, however are not yet
known. The dorsal and medial raphe nuclei which are rich in
5-HT containing cell bodies have been shown to ascend to the
hypothalamus and therefore, are likely candidates for mediating
5-HT induced changes in CRH secretion. General evidence for an
involvement of extrahypothalamic pathways is provided in a study
by Karteszi et al. (1982) who reported that anterolateral
deaf ferentat ion of the hypothalamus greatly reduced the
corticosterone rise seen in response to insulin. In contrast,
however, Aizawa, Yasuda and Greer (1981) have shown that com-
plete hypothalamic isolation did not prevent the corticosterone
54
response to insulin. The latter finding would be more consistent
with a possible involvement of serotonergic neurons within the
hypothalamus itself (Kent & Sladek, 1981). Evidence for the
existence of 5-HT nerve terminals in the hypothalamus which
stimulates CRH release have already been clearly demonstrated
in the in vitro studies mentioned in the Introduction. Therefore,
it is possible that these recently discovered 5-HT neurons within
the hypothalamus may act to mediate pituitary-adrenal activity.
More studies will be needed to resolve this issue.
Although questions still remain the present research demon-
strates a serotonergic mediation of the pituitary-adrenal
response to insulin stress which most likely depends on increased
tryptophan availability. Other studies have similarly shown a
correlation between pituitary-adrenal stimulation and increased
brain tryptophan in response to immobilization stress (Curzon,
Joseph & Knott, 1973; Mueller et al.
,
1976; Kenneth & Joseph,
1981)
.
These studies showed comparable endocrine responses to
tryptophan administration and immobilization, and in one case
demonstrated that valine pretreatment reduced both the brain
tryptophan and adrenocortical effects following immobilization
(Kenneth & Joseph, 1981). In other experiments, restraint stress
(Knott, Joseph & Curzon, 1973) and novelty stress (Knott, Hutson
& Curzon, 1977) were associated with increased plasma levels of
NEFA, suggesting that the increase in brain tryptophan seen in
response to these stressors may reflect an increased availability
of free tryptophan. Thus, changes in brain 5-HT mediated
altered tryptophan availability may be important in the
pituitary-adrenal response to a variety of stressors.
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